KR20040087111A - 백내장 질환 모델마우스 및 그의 생산방법 - Google Patents
백내장 질환 모델마우스 및 그의 생산방법 Download PDFInfo
- Publication number
- KR20040087111A KR20040087111A KR1020030021367A KR20030021367A KR20040087111A KR 20040087111 A KR20040087111 A KR 20040087111A KR 1020030021367 A KR1020030021367 A KR 1020030021367A KR 20030021367 A KR20030021367 A KR 20030021367A KR 20040087111 A KR20040087111 A KR 20040087111A
- Authority
- KR
- South Korea
- Prior art keywords
- mouse
- cataract
- mice
- asc
- recombinant plasmid
- Prior art date
Links
- 208000002177 Cataract Diseases 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims description 15
- 238000004519 manufacturing process Methods 0.000 title abstract description 10
- 101710115514 Nuclear receptor coactivator 6 Proteins 0.000 claims abstract description 27
- 102100022929 Nuclear receptor coactivator 6 Human genes 0.000 claims abstract description 25
- 239000013612 plasmid Substances 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 51
- 241000699670 Mus sp. Species 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 235000013601 eggs Nutrition 0.000 claims description 25
- 238000011830 transgenic mouse model Methods 0.000 claims description 14
- 241000699660 Mus musculus Species 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 238000011161 development Methods 0.000 abstract description 7
- 210000001508 eye Anatomy 0.000 description 45
- 230000007547 defect Effects 0.000 description 10
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 8
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 8
- 102000006255 nuclear receptors Human genes 0.000 description 8
- 108020004017 nuclear receptors Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108091006108 transcriptional coactivators Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 201000003043 Persistent hyperplastic primary vitreous Diseases 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108010062495 Mediator Complex Subunit 1 Proteins 0.000 description 2
- 102000010904 Mediator Complex Subunit 1 Human genes 0.000 description 2
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 2
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000010291 electrical method Methods 0.000 description 2
- 230000000408 embryogenic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 description 1
- GMGWOTQMUKYZIE-UBHSHLNASA-N Ala-Pro-Phe Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GMGWOTQMUKYZIE-UBHSHLNASA-N 0.000 description 1
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 1
- FTSAJSADJCMDHH-CIUDSAMLSA-N Asn-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N FTSAJSADJCMDHH-CIUDSAMLSA-N 0.000 description 1
- GKKUBLFXKRDMFC-BQBZGAKWSA-N Asn-Pro-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O GKKUBLFXKRDMFC-BQBZGAKWSA-N 0.000 description 1
- 206010048632 Atrial thrombosis Diseases 0.000 description 1
- 238000012756 BrdU staining Methods 0.000 description 1
- 229920000818 Catalin Polymers 0.000 description 1
- VCIIDXDOPGHMDQ-WDSKDSINSA-N Cys-Gly-Gln Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O VCIIDXDOPGHMDQ-WDSKDSINSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- SOBBAYVQSNXYPQ-ACZMJKKPSA-N Gln-Asn-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SOBBAYVQSNXYPQ-ACZMJKKPSA-N 0.000 description 1
- LHMWTCWZARHLPV-CIUDSAMLSA-N Gln-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LHMWTCWZARHLPV-CIUDSAMLSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- QAMFAYSMNZBNCA-UWVGGRQHSA-N His-Gly-Met Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O QAMFAYSMNZBNCA-UWVGGRQHSA-N 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- RIJCHEVHFWMDKD-SRVKXCTJSA-N Lys-Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RIJCHEVHFWMDKD-SRVKXCTJSA-N 0.000 description 1
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 1
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
- 208000009795 Microphthalmos Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- HNFUGJUZJRYUHN-JSGCOSHPSA-N Phe-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HNFUGJUZJRYUHN-JSGCOSHPSA-N 0.000 description 1
- ZLAKUZDMKVKFAI-JYJNAYRXSA-N Phe-Pro-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O ZLAKUZDMKVKFAI-JYJNAYRXSA-N 0.000 description 1
- 208000016012 Phenotypic abnormality Diseases 0.000 description 1
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N Pirenoxine Chemical compound C12=NC3=CC=CC=C3OC2=CC(=O)C2=C1C(=O)C=C(C(=O)O)N2 OKPNYGAWTYOBFZ-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- QSKCKTUQPICLSO-AVGNSLFASA-N Pro-Arg-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O QSKCKTUQPICLSO-AVGNSLFASA-N 0.000 description 1
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 1
- 102100020847 Protein FosB Human genes 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 208000004453 Retinal Dysplasia Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- IXUGADGDCQDLSA-FXQIFTODSA-N Ser-Gln-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N IXUGADGDCQDLSA-FXQIFTODSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 description 1
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 1
- 108010042291 Serum Response Factor Proteins 0.000 description 1
- 102100022056 Serum response factor Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- SWIKDOUVROTZCW-GCJQMDKQSA-N Thr-Asn-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O SWIKDOUVROTZCW-GCJQMDKQSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- -1 catachrome Chemical compound 0.000 description 1
- XFQYJNINHLZMIU-UHFFFAOYSA-N cataline Natural products CN1CC(O)C2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 XFQYJNINHLZMIU-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- HPAIKDPJURGQLN-UHFFFAOYSA-N glycyl-L-histidyl-L-phenylalanine Natural products C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(NC(=O)CN)CC1=CN=CN1 HPAIKDPJURGQLN-UHFFFAOYSA-N 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 201000010478 microphthalmia Diseases 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D35/00—Filtering devices having features not specifically covered by groups B01D24/00 - B01D33/00, or for applications not specifically covered by groups B01D24/00 - B01D33/00; Auxiliary devices for filtration; Filter housing constructions
- B01D35/14—Safety devices specially adapted for filtration; Devices for indicating clogging
- B01D35/157—Flow control valves: Damping or calibrated passages
- B01D35/1573—Flow control valves
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
표현형 이상 | 형질전환 마우스 DN1 TG | ||||
#54 | #71 | #84 | #87 | #104 | |
눈배아의 눈- 소형눈(microphthalmia)- 망막형성 장애: 망막의 접힘 현상- 공막의 부분결손(thinner or missing)- 수정체핵후막(retrolenticular membrane)- PHPV- 백내장성체의 눈- 후부 원추수정체- 백내장- 소형눈- 망막형성 장애- 공막의 부분결손- 수정체핵후막- PHPV | +*+*+*+*+*+*+*+*+*+*+*+*+* | -------+¶+¶---- | +*+*+*+*+*+*+*+*+*+*+*+*+* | NANANANANANANA+§+§NANANANA | -------+¶+¶---- |
심장배아의 심장- 심실 격막 결함성체의 심장- 심방 혈전증- 비대증- 전도작용 결함 | ND--- | ND+++ | +--- | ND++ND | ND+++ |
호흡기- 폐 저형성(hypoplasia)- 폐 출혈(congestion)- 폐 염증 | --- | +++ | --- | +++ | +++ |
간: 지방간 | - | + | - | + | + |
흉선 위축: 발육부전(agenesis) | - | + | - | + | + |
비장 위축 | - | + | - | + | + |
방광 수증(hydrops) | - | + | - | + | + |
신장 저형성 | - | + | - | + | + |
뇌하수체 적화(redness): 팽창 | - | + | - | + | + |
부신선 적화 | - | + | - | + | + |
운동 결함: 로타-로드 활성결함 | + | ND | + | ND | ND |
Claims (8)
- (ⅰ) ASC-2의 N-말단 LXXLL 모티프를 포함하는 단편을 암호화하는 DNA 서열을 포함하는 재조합 플라스미드를 작제하는 단계;(ⅱ) 전기 재조합 플라스미드를 마우스의 수정란으로 도입시키는 단계;(ⅲ) 재조합 플라스미드가 도입된 수정란을 발생시켜 형질전환 마우스를 수득하는 단계; 및,(ⅳ) 전기 수득된 마우스의 표현형을 조사하여 백내장 질환 모델마우스를 선별하는 단계를 포함하는 백내장 질환 모델마우스의 생산방법.
- 제 1항에 있어서,ASC-2 단백질의 N-말단 LXXLL 모티프를 포함하는 단편은 50 내지 100 개의 아미노산 잔기로 구성되는 것을 특징으로 하는백내장 질환 모델마우스의 생산방법.
- 제 1항에 있어서,ASC-2 단백질의 N-말단 LXXLL 모티프를 포함하는 단편은 DN1(서열번호 1)인 것을 특징으로 하는백내장 질환 모델마우스의 생산방법.
- 제 1항에 있어서,재조합 플라스미드는 DN1/pCAGGS인 것을 특징으로 하는백내장 질환 모델마우스의 생산방법.
- 제 1항에 있어서,수정란은 FVB주 마우스의 수정란인 것을 특징으로 하는백내장 질환 모델마우스의 생산방법.
- 재조합 플라스미드 DN1/pCAGGS를 포함하는 마우스의 수정란인 퍼틸라이즈드 에그 프럼 DN1 트랜스지닉 마이스(Fertilized eggs from DN1 transgenic mice, KCTC 10419BP).
- 제 1항의 방법으로 생산된 백내장 질환 모델마우스.
- 제 7항의 마우스로부터 생산되는 자손 마우스.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0021367A KR100518647B1 (ko) | 2003-04-04 | 2003-04-04 | 백내장 질환 모델마우스 및 그의 생산방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0021367A KR100518647B1 (ko) | 2003-04-04 | 2003-04-04 | 백내장 질환 모델마우스 및 그의 생산방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040087111A true KR20040087111A (ko) | 2004-10-13 |
KR100518647B1 KR100518647B1 (ko) | 2005-10-04 |
Family
ID=37369334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0021367A KR100518647B1 (ko) | 2003-04-04 | 2003-04-04 | 백내장 질환 모델마우스 및 그의 생산방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100518647B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112220446A (zh) * | 2020-10-28 | 2021-01-15 | 中国人民解放军陆军特色医学中心 | 一种小鼠白内障检测设备 |
-
2003
- 2003-04-04 KR KR10-2003-0021367A patent/KR100518647B1/ko active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112220446A (zh) * | 2020-10-28 | 2021-01-15 | 中国人民解放军陆军特色医学中心 | 一种小鼠白内障检测设备 |
CN112220446B (zh) * | 2020-10-28 | 2024-01-30 | 中国人民解放军陆军特色医学中心 | 一种小鼠白内障检测设备 |
Also Published As
Publication number | Publication date |
---|---|
KR100518647B1 (ko) | 2005-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma | |
Lamb et al. | Drosophila coracle, a member of the protein 4.1 superfamily, has essential structural functions in the septate junctions and developmental functions in embryonic and adult epithelial cells | |
Karali et al. | Localization of myocilin/trabecular meshwork–inducible glucocorticoid response protein in the human eye | |
Maitra et al. | The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling | |
Lőrincz et al. | MiniCORVET is a Vps8-containing early endosomal tether in Drosophila | |
Mandal et al. | Spatial and temporal expression of MFRP and its interaction with CTRP5 | |
Fogerty et al. | 174delG mutation in mouse MFRP causes photoreceptor degeneration and RPE atrophy | |
Daniele et al. | Mutation of wrb, a component of the guided entry of tail-anchored protein pathway, disrupts photoreceptor synapse structure and function | |
Cho et al. | Dlg1 activates beta-catenin signaling to regulate retinal angiogenesis and the blood-retina and blood-brain barriers | |
US8779093B2 (en) | Neuronal viability factor and use thereof | |
Duncan et al. | Truncated forms of Pax-6 disrupt lens morphology in transgenic mice | |
Kivelä et al. | Ezrin, a membrane-organizing protein, as a polarization marker of the retinal pigment epithelium in vertebrates | |
Huang et al. | Highroad is a carboxypetidase induced by retinoids to clear mutant Rhodopsin-1 in Drosophila Retinitis Pigmentosa Models | |
DE60127982T2 (de) | Transgene drosophila melanogaster, die beta-amyloid exprimiert | |
Esposito et al. | Diurnal photoreceptor outer segment renewal in mice is independent of galectin-3 | |
SCHÜTTE et al. | Connexin50, a gap junction protein of macroglia in the mammalian retina and visual pathway | |
KR100518647B1 (ko) | 백내장 질환 모델마우스 및 그의 생산방법 | |
Li et al. | Piccolo is essential for the maintenance of mouse retina but not cochlear hair cell function | |
US20060058504A1 (en) | Peptides capable of inducing attraction to the axonal growth and their use for treating neurodegenerative diseases | |
KR102040893B1 (ko) | Arl6ip1의 유전성 강직성 하반신마비의 치료 용도 | |
Kivelä | Parvalbumin, a horizontal cell-associated calcium-binding protein in retinoblastoma eyes. | |
JP2002363107A (ja) | 色覚不全動物の色覚復元方法 | |
Jentzsch et al. | A new preclinical model of retinitis pigmentosa due to Pde6g deficiency | |
KR101567921B1 (ko) | Otx2 단백질을 유효성분으로 포함하는 미토콘드리아 이상질환 예방 및 치료용 조성물 | |
Kang et al. | Tweek-dependent formation of ER-PM contact sites enables astrocyte phagocytic function and remodeling of neurons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130923 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140709 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150901 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160729 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170926 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180709 Year of fee payment: 14 |